8-K

                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): October 28, 2004.

                                  BioTime, Inc.
             (Exact name of registrant as specified in its charter)

        California                      1-12830                  94-3127919
(State or other jurisdiction    (Commission File Number)     (IRS Employer
of incorporation)                                            Identification No.)

                                935 Pardee Street
                           Berkeley, California 94710
                    (Address of principal executive offices)

                          (510) 845-9535 (Registrant's
                     telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

|_| Written communications pursuant to Rule 425 under the Securities Act
    (17 CFR 230.425)

|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act
    (17 CFR 240.14a-12)

|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
    Act (17 CFR 240.14d-2(b))

|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
    Act (17 CFR 240.13e-4(c))


      Statements made in this Report that are not historical facts may
constitute forward-looking statements that are subject to risks and
uncertainties that could cause actual results to differ materially from those
discussed. Such risks and uncertainties include but are not limited to those
discussed in this report and in BioTime's Annual Report on Form 10-K filed with
the Securities and Exchange Commission. Words such as "expects," "may," "will,"
"anticipates," "intends," "plans," "believes," "seeks," "estimates," and similar
expressions identify forward-looking statements.

Section 5- Corporate Governance and Management

Item 5.02. Departure of Directors or Principal Officers; Election of Directors;
Appointment of Principal Officers.

      On October 28, 2004, the Board of Directors elected Valeta A. Gregg,
Ph.D., J.D. to the Board. Dr. Gregg is Vice President & Assistant General
Counsel, Patents for Regeneron Pharmaceuticals, Inc., a Tarrytown, New York
based company engaged in the development of pharmaceutical products for the
treatment of a number of serious medical conditions, including cancer, diseases
of the eye, rheumatoid arthritis and other inflammatory conditions, allergies,
asthma, and obesity. In her capacity at Regeneron Pharmaceuticals, Dr. Gregg is
responsible for company-wide patent-related activities. Prior to joining
Regeneron Pharmaceuticals, Dr. Gregg was Senior Patent Attorney for Novo Nordisk
of North America.

      Dr. Gregg received her J.D. from the University of Colorado School of Law
in 1992. She completed her Ph.D. in Biochemistry at the University of Alberta,
Edmonton Alberta Canada in 1982 and was a Post-Doctorial Fellow at Columbia
University from 1983-1986. Dr. Gregg conducted her undergraduate and graduate
studies in Human Nutrition at the University of California at Davis (M.S. 1977;
B.S., 1975)

      Although the Board has not yet determined whether Dr. Gregg will be
appointed to any of its committees, as an independent director, within the
meaning of American Stock Exchange Rule 121A, she is eligible to serve on the
Board's Audit, Compensation and Nominating Committees.

      Dr. Gregg is replacing Jeffrey B. Nickel, Ph.D. on the Board. Dr. Nickel
has stepped down in order to focus on his duties as Vice President of Business
Development and Marketing. Dr. Nickel was appointed to that position effective
June 1, 2004.


                                       2


                                   SIGNATURES

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                                      BIOTIME, INC.

Date: November 2, 2004                                By /s/ Steven Seinberg
                                                         -----------------------
                                                         Steven Seinberg,
                                                         Chief Financial Officer


                                       3


Exhibit
Numbers     Description
- --------    -----------

99.1        Press Release dated November 2, 2004

EX-99.1

                                                                    Exhibit 99.1

     Valeta A. Gregg, Ph.D., J.D. Joins BioTime, Inc. Board Of Directors

    BERKELEY, Calif., Nov. 2 /PRNewswire-FirstCall/ -- BioTime, Inc.
(Amex: BTX) announced today that Valeta A. Gregg, Ph.D., J.D., has been
elected to BioTime's Board of Directors.  Dr. Gregg currently serves as Vice
President & Assistant General Counsel, Patents, for Regeneron Pharmaceuticals,
Inc. and will be replacing Jeffrey B. Nickel, Ph.D. on BioTime's Board.
Dr. Nickel stepped down in order to focus on his new duties as BioTime's Vice
President of Business Development and Marketing.
    "Dr. Gregg's strong background as a top patent attorney in the
biotechnology and pharmaceutical industries brings additional expertise to our
Board of Directors," said Judith Segall, Vice President of Operations and
member of the Office of the President at BioTime.  "While at Fish &
Richardson, P.C. in the mid-1990s, Valeta Gregg provided counsel to the
Company and was instrumental in the early development of BioTime's patent
portfolio.  Her wealth of knowledge in patent law and contributions to the
Board will be valuable as BioTime develops and commercializes new products."
    Since 2002, Dr. Gregg has been employed at Regeneron Pharmaceuticals, a
Tarrytown, New York based company engaged in the development of pharmaceutical
products for the treatment of a number of serious medical conditions,
including cancer, diseases of the eye, rheumatoid arthritis and other
inflammatory conditions, allergies, asthma, and obesity.  In her capacity at
Regeneron Pharmaceuticals, Dr. Gregg is responsible for company-wide
patent-related activities.  Prior to joining Regeneron Pharmaceuticals,
Dr. Gregg was Senior Patent Attorney for Novo Nordisk of North America.
    Dr. Gregg received her J.D. from the University of Colorado School of Law
(1992).  She completed her Ph.D. in Biochemistry at the University of Alberta,
Edmonton Alberta Canada (1982) and was a Post-Doctorial Fellow at Columbia
University (1983-1986).  She conducted her undergraduate and graduate studies
in Human Nutrition at the University of California at Davis (M.S. 1977; B.S.,
1975).

    About BioTime, Inc.
    BioTime, headquartered in Berkeley, California develops blood plasma
volume expanders, blood replacement solutions for hypothermic (low
temperature) surgery, organ preservation solutions and technology for use in
surgery, emergency trauma treatment and other applications.  BioTime's lead
product Hextend(R) is manufactured and distributed in the U.S. and Canada by
Hospira, Inc. under an exclusive licensing agreement.  Information about
BioTime can be found on the web at www.biotimeinc.com.

    Forward Looking Statements
    The matters discussed in this press release include forward-looking
statements which are subject to various risks, uncertainties and other factors
that could cause actual results to differ materially from the results
anticipated.  Such risks and uncertainties include but are not limited to the
results of clinical trials of BioTime products; the ability of BioTime and its
licensees to obtain additional FDA and foreign regulatory approval to market
BioTime products; competition from products manufactured and sold or being
developed by other companies; and the price of and demand for BioTime
products.  Other risk factors are discussed in BioTime's Annual Report on Form
10-K filed with the Securities and Exchange Commission.

SOURCE  BioTime, Inc.
    -0-                             11/02/2004
    /CONTACT:  Judith Segall, Vice President of Operations, The Office of the
President of BioTime, Inc., +1-510-845-9535; or Lasse Glassen,
Investor/Analyst Information of Financial Relations Board, +1-310-854-8313,
lglassen@financialrelationsboard.com, for BioTime, Inc./
    /Web site:  http://www.biotimeinc.com /
    (BTX)

CO:  BioTime, Inc.
ST:  California
IN:  MTC HEA BIO
SU:  PER